Lenalidomide/Anti-CD19 Antibody Combo Yields Encouraging Results in Poor-Prognosis DLBCL

Researchers studied the Fc-enhanced, humanized anti-CD19 antibody MOR208 combined with lenalidomide in  relapsed/refractory large B-cell lymphoma.

Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news